Ottawa, January 5, 2024 – Innovative Medicines Canada (IMC) is deeply concerned with the U.S. Food and Drug Administration’s (FDA) decision to allow Florida to import drugs from Canada.
“Canada simply can’t supply drugs to Florida, or any other U.S. states, without significantly increasing the risk and severity of drug shortages nationwide. The U.S. market is nearly 10 times bigger than Canada’s, and allowing drugs that were intended for Canadians to be exported to the U.S. would harm Canadian patients and disrupt our health-care system,” said David Renwick, Interim President of Innovative Medicines Canada.
IMC and its members remain committed to working with Health Canada and other stakeholders to safeguard drug supply for Canadian patients.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 48 companies that invest nearly $1.4 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
For further information:
Marise Varanda
Director, Media Relations & Content
Telephone: 613-462-5367
E-mail: media@imc-mnc.ca
